Tricyclic Antidepressants in Children: Is There a Rationale for Use?

CNS Drugs

Volumn 5, Issue 4, 1996, Pages 233-239

  Hazell, Philip ^a  

^a UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ANXIETY; ATTENTION DEFICIT DISORDER; CHILD; CHILDHOOD DISEASE; COMPULSION; DEPRESSION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; GILLES DE LA TOURETTE SYNDROME; HUMAN; HYPERACTIVITY; OBSESSION; PRIORITY JOURNAL; PSYCHOTHERAPY; SHORT SURVEY; SIDE EFFECT;

EID: 0029976434     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199605040-00001     Document Type: Review

References (42)

1. Riddle MA. Pharmacokinetics in children and adolescents. In: Lewis M, editor. Child and adolescent psychiatry. A comprehensive textbook. Baltimore: Williams and Wilkins, 1991: 767-70
2. Geller B. Psychopharmacology of children and adolescents: pharmacokinetics and relationships of plasma/serum levels to response. Psychopharmacol Bull 1991; 27: 401-9
3. Ryan ND. The pharmacologic treatment of child and adolescent depression. Psychiatr Clin North Am 1992; 15: 29-39
4. Schmitt B. Efficacy and safety of drugs available for the treatment of nocturnal enuresis. Drug Invest 1990; 2 Suppl. 5: 9-16
5. Miller K, Atkin B, Moody ML. Drug therapy for nocturnal enuresis: current treatment recommendations. Drugs 1992; 44: 47-56
6. Rapoport JL, Mikkelson EJ, Zavadil A, et al. Childhood enuresis: psychopathology, tricyclic concentration in plasma and antienuretic effect. Arch Gen Psychiatry 1980; 3: 1146-52
7. Thomas JM. Antidepressants in the treatment of attention deficit hyperactivity disorder. In: Accardo PJ, Blondis TA, Whitman BY, editors. Attention deficit disorders and hyperactivity in children. New York: Dekker, 1991: 333-74
8. Garfinkel BD, Wender PH, Sloman L, et al. Tricyclic antidepressant and methylphenidate treatment of attention deficit disorder in children. J Am Acad Child Adolesc Psychiatry 1983; 22: 343-8
9. Spencer T, Biederman J, Wilens T, et al. Nortriptyline in the treatment of children with attention deficit hyperactivity disorder and tic disorder or Tourette's syndrome. J Am Acad Child Adolesc Psychiatry 1993; 32: 205-10
10. Parraga HC, Cochran MK. Emergence of motor and vocal tics during imipramine administration in two children. J Child Adolesc Psychopharmacol 1992; 2: 227-34
11. Ryan N. Heterocyclic antidepressants in children and adolescents. J Child Adolesc Psychopharmacol 1990; 1: 21-31
12. DeVaugh-Geiss J, Moroz G, Biederman J, et al. Clomipramine hydrochloride in childhood and adolescent obsessive-compulsive disorder - a multicenter trial. J Am Acad Child Adolesc Psychiatry 1992; 31: 45-9
13. Gittelman-Klein R, Klein DF. Controlled imipramine treatment of school phobia. Arch Gen Psychiatry 1971; 25: 204-7
14. Berney T, Kolvin I, Bhate SR, et al. School phobia: a therapeutic trial with clomipramine and short-term outcome. Br J Psychiatry 1981; 138: 110-8
15. Klein RG, Koplewicz HS, Kanner A. Imipramine treatment of children with separation anxiety disorder. J Am Acad Child Adolesc Psychiatry 1992; 31: 21-8
16. Singer HS, Brown J, Quaskey S, et al. The treatment of attention-deficit hyperactivity disorder in Tourette's syndrome: a double-blind placebo-controlled study with clonidine and desipramine. Pediatrics 1995; 95: 74-81
17. Ambrosini PJ, Bianchi MD, Rabinovich H, et al. Antidepressant treatments in children and adolescents: I. Affective disorders. J Am Acad Child Adolesc Psychiatry 1993; 32: 1-6
18. Elliott GR. Dilemmas for clinicians and researchers using antidepressants to treat adolescents with depression. J Child Adolesc Psychopharmacol 1992; 2: 7-9
19. Popper C. Are clinicians ahead of researchers in finding a treatment for adolescent depression? J Child Adolesc Psychopharmacol 1992; 2: 1-3
20. Strober M. The pharmacotherapy of depressive illness in adolescence: III. Diagnostic and conceptual issues in studies of tricyctic antidepressants. J Child Adolesc Psychopharmacol 1992; 2: 23-9
21. Taylor E. Commissioned review - psychopharmacology in childhood. Newslett Assoc Child Psychol Psychiatry 1988; 10: 3-6
22. Weller EB, Weller RA. Mood disorders. In: Lewis M, editor. Child and adolescent psychiatry. A comprehensive textbook. Baltimore: Williams and Wilkins, 1991: 646-64
23. Geller B. Should tricyclic antidepressants be prescribed to depressed children and adolescents? Curr Opin Psychiatry 1994; 7: 301-3
24. Jensen PS, Ryan ND, Prien R. Psychopharmacology of child and adolescent major depression: present status and future directions. J Child Adolesc Psychopharmacol 1992; 2: 31-45
25. Hazell P, O'Connell D, Heathcote D, et al. Efficacy of tricyclic drugs in child and adolescent depression: a meta-analysis. BMJ 1995; 310: 897-901
26. Kramer AD, Feguine RJ. Clinical effects of amitriptyline in adolescent depression. J Am Acad Child Psychiatry 1981; 20: 636-44
27. Kashani JH, Shekim WO, Reid JC. Amitriptyline in children with major depressive disorders: a double-blind crossover pilot study. J Am Acad Child Psychiatry 1984; 23: 348-51
28. Preskorn SH, Weller EB, Weller RA. Depression in children: relationship between plasma imipramine levels and response. J Clin Psychiatry 1982; 43: 450-3
29. Bernstein GA, Garfinkel BD, Borchardt CM. Comparative studies of pharmacotherapy for school refusal. J Am Acad Child Adolesc Psychiatry 1990; 29: 773-81
30. Hughes CW, Preskorn SH, Weller E, et al. The effect of concomitant disorders in childhood depression on predicting treatment response. Psychopharmacol Bull 1990; 26: 235-8
31. Boulos C, Kutcher S, Marton P, et al. Response to desipramine treatment in adolescent major depression. Psychopharmacol Bull 1991; 27: 59-65
32. Geller B, Cooper TB, McCombs HG, et al. Double-blind, placebo-controlled study of nortriptyline in depressed children using a 'fixed plasma level' design. Psychopharmacol Bull 1989; 25: 101-8
33. Geller B, Cooper TB, Graham DL, et al. Pharmacokinetically designed double-blind placebo-controlled study of nortriptyline in 6-12 year-olds with major depressive disorder. J Am Acad Child Adolesc Psychiatry 1992; 31: 34-44
34. Puig-Antich J, Perel JM, Lupatkin W, et al. Imipramine in prepubertal major depressive disorders. Arch Gen Psychiatry 1987; 44: 81-9
35. Riddle M, Geller B, Ryan N. Another sudden death in a child treated with desipramine. J Am Acad Child Adolesc Psychiatry 1993; 32: 792-7
36. Geller B, Fox LW, Fletcher M. Effect of tricyclic antidepressants on switching to mania and the later onset of bipolarity in depressed 6-12 year olds from the nortriptyline drug study. J Am Acad Child Adolesc Psychiatry 1993; 32: 43-50
37. Burke MS, Josephson A, Lightsey A. Combined methylphenidate and imipramine complication [letter]. J Am Acad Child Adolesc Psychiatry 1995; 34: 403-4
38. Popper C. Medical unknowns and ethical consent: prescribing psychotropic medications for children in the face of uncertainty. In: Popper C, editor. Psychiatric pharmacosciences of children and adolescents. Washington, DC: American Psychiatric Press, 1987: 127-61
39. Elia J. Stimulants and antidepressant pharmacokinetics in hyperactive children. Psychopharmacol Bull 1991; 27: 411-5
40. Ryan ND, Puig-Antich J, Cooper TB, et al. Relative safety of single versus divided dose imipramine in adolescent major depression. J Am Acad Child Adolesc Psychiatry 1987; 26: 400-6
41. Petti T. Scales of potential use in the psychopharmacological treatment of depressed children and adolescents. Psychopharmacol Bull 1985; 21: 951-77
42. Wilens TE, Spencer T, Biederman J, et al. Combined pharmacotherapy: an emerging trend in pediatric psychopharmacology. J Am Acad Child Adolesc Psychiatry 1995; 34: 110-2